2缺血性脑血管急性期的一般处理上海教材.ppt

SPAN-100：颅内出血和良好预后 Neurology. 2013 Jan 1;80(1):21-8 三个月功能愈后 VALIDATION OF SPAN INDEX IN CNSR Endpoints AUC IS patients ICH patients IS+ICH 3 months mRS 2-6 0.724 0.757 0.730 mRS 3-6 0.759 0.770 0.759 Death 0.776 0.763 0.771 Stroke recurrence 0.629 0.713 0.645 6 months mRS 2-6 0.746 0.757 0.747 mRS 3-6 0.771 0.779 0.771 Death 0.791 0.762 0.780 Stroke recurrence 0.645 0.684 0.652 12 months mRS 2-6 0.748 0.765 0.751 mRS 3-6 0.780 0.778 0.778 Death 0.791 0.766 0.782 Stroke recurrence 0.571 0.599 0.575 * SPAN index as continuous variable VALIDATION OF SPAN100 IN CNSR Endpoints AUC IS patients ICH patients IS+ICH 3 months mRS 2-6 0.538 0.562 0.544 mRS 3-6 0.551 0.572 0.557 Death 0.614 0.610 0.614 Stroke recurrence 0.535 0.577 0.542 6 months mRS 2-6 0.539 0.564 0.545 mRS 3-6 0.552 0.576 0.559 Death 0.609 0.605 0.609 Stroke recurrence 0.538 0.566 0.543 12 months mRS 2-6 0.540 0.566 0.547 mRS 3-6 0.554 0.576 0.560 Death 0.599 0.605 0.602 Stroke recurrence 0.519 0.545 0.522 * SPAN100 as categorial variables: SPAN index≥ 100 vs 100. Distribution of mRS by span100 categories in ICH patients in CNSR Distribution of mRS by span100 categories in IS patients in CNSR Distribution of mRS by span100 categories in IS+ICH patients in CNSR 影响预后的因素 谢谢 * yongjunwang1962@ * Intensive treatment nomogram by intravenous continuous insulin (A) and subcutaneous insulin (B). Flowchart of the study according to the CONSORT (CONsolidated Standards of Reporting Trials) guidelines. CGT indicates capillary glucose test; SC, subcutaneous; IV, intravenous. Impact of treatment group on glycemic control. Mean capillary blood glucose test at admission, H4, H8, H12, H16, H20, and H24 after treatment allocation in the IIT and the SIT groups. Proportions of patients with CGT 7 mmol/L are indicated on the graph at each time point and they were all significantly different. The repeated-measure ANOVA showed a significant treatment group effect (F[1, 163]=19.8, P0.0001) with a significant time effect (F